As per the deal, Novartis Pharma will be responsible for the supply of Galvus and Galvus Met to DRL at a predetermined price. Credit: fizkes/ Shutterstock.com.

Dr. Reddy’s Laboratories’ Russian subsidiary has signed an agreement with Novartis Pharma to carry out the sale and distribution of the anti-diabetes products, Galvus and Galvus Met.

Recommended Buyer's Guides

The distribution agreement outlines that Dr. Reddy’s Laboratories LLC, Russia (DRL) will distribute these products within the retail sector and engage with healthcare specialists through its own sales force and pharmacy chain management.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This deal does not include a licensing fee, upfront, or down-payment.

Galvus and Galvus Met are prominent assets in the Dipeptidyl Peptidase-4 (DPP4) inhibitor category, with combined sales of nearly $30m as per IQVIA Moving Annual Total (MAT) March 2024, in the Russian retail market.

As per the deal, Novartis Pharma will be responsible for the supply of Galvus and Galvus Met to DRL at a predetermined price and offer bonuses based on the achievement of key performance indicators (KPIs).

See Also:

DRL is expected to place purchase orders according to a rolling forecast and meet specific volume KPIs for each reporting period.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The service agreement to be signed in the future will define the scope of work for this distribution arrangement between DRL and Novartis Pharma.

This partnership is a strategic move for DRL as it aims to expand into the cardio and diabetes therapeutic areas.

In addition, the latest deal could pave the way for future cooperation between DRL and Novartis Pharma in the cardiovascular domain.

The announcement follows a recent collaboration between Dr. Reddy’s Laboratories and Alvotech, focusing on the commercialisation of AVT03 in the US, Europe, and the UK.

AVT03 is a biosimilar candidate to the reference products Prolia and Xgeva (denosumab).

Prolia and Xgeva are intended to treat osteoporosis in postmenopausal women and prevent skeletal-related events in adults with advanced cancers.